August 6, 2021 -- 10x Genomics reported revenue growth in the second quarter of 2021 of 170% over the same quarter a year ago.
The company said revenue for the second quarter was $115.8 million (end-June 30, 2021), up from $42.9 million in the second quarter of 2020. The increase can be attributed to greater consumables revenue driven by growth in the instrument-installed base, along with the decreased impact of the pandemic on customer operations, 10x Genomics added.
Among the highlights for the quarter, the company launched its single cell analysis platform Chromium X; began shipping Visium Spatial Gene Expression for formalin-fixed, paraffin-embedded (FFPE) samples; and entered into a global settlement and cross-license agreement with Bio-Rad Laboratories.
Copyright © 2021 scienceboard.net